Phase 1 N=124 Telerehabilitation in the Home Versus Therapy In-Clinic for Patients With Stroke
Stroke
Primary: Change in Arm Motor Fugl-Meyer Score From Baseline to 30 Days Post-therapy — 7.86; 8.36 units on a scale — p=.96
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=60 Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169
Healthy Subjects
Primary: Number of Adverse Events — 9; 4; 5; 2 AEs
Phase 1 N=61 A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
Non-hematologic Malignancy
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 7; 6; 9; 11 Participants
Phase 1 N=21 Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen
Vasomotor Symptoms (VMS)
Primary: Adverse Event (AE) Reporting of Q-122 — 7; 7 Participants
Phase 1 N=44 Safety and Efficacy Study of DAV132 in Healthy Volunteers
Healthy
Primary: Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 16 Days After…
Phase 1 N=30 Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment
Renal Impairment · Healthy
Primary: Cmax — 545.4; 593.2; 475.9 ng/mL
Phase 1 N=14 A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants
Healthy Volunteers
Primary: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of Entrectinib and M5 Metabolite — 44000; 44900; 14400; 15000 nmol*h/L
Phase 1 N=81 A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Advanced Nonhematologic Malignancies
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 4; 3; 7; 3 Participants
Phase 1 N=30 Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers
Healthy Adult Volunteers
Primary: Number of Participants With of Adverse Events — 5; 9; 4 Participants
Phase 1 N=16 A Study Investigating the Absolute Oral Bioavailability of Balovaptan After Single and Multiple Daily Oral Doses of Balovaptan in Healthy Volunteers
Healthy Volunteers
Primary: Absolute Bioavailability of Oral Balovaptan at Dose Level A (Cohort 1) — 100.6 Percentage
Phase 1 N=47 A Study to Characterize Diclofenac's Plasma and Knee Exposure After Application of Diclofenac Gel to the Knee of Subjects With Osteoarthritis That Have a Scheduled Arthroplasty
Pain
Primary: Diclofenac Concentration in Treated Knee Synovial Tissue After 7 Days Topical Application of Study Treatment to the Knee (12 Hours After Last Administration of Study…
Phase 1 N=30 This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
Healthy
Primary: Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2134.53; 2125.57…
Phase 1 N=50 Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets
Healthy
Primary: Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz) — 5990…
Phase 1 N=30 This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) for Empagliflozin — 5656.07…
Phase 1 N=48 Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
HIV-1 Infection
Primary: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) and Any Treatment-Emergent Adverse Events (AEs). — 0.0; 16.7; 0.0; 0.0…